Aquestive Therapeutics Inc. (NASDAQ: AQST) reported Q4 EPS of ($0.56), $0.05 worse than the analyst estimate of ($0.51). Revenue for the quarter came in at $16.8 million versus the consensus estimate of $16.69 million.

"Aquestive made significant progress in 2018 by launching our first proprietary product and continuing our transformation into a commercial-stage, specialty pharmaceutical company," said Keith J. Kendall, Chief Executive Officer of Aquestive. "As requested by the FDA in our meeting with them in late December, we have initiated the crossover study for Libervant. We are also moving forward with our plans to file Libervant and an additional NDA for Exservan in 2019. Along with this activity, we are advancing early stage assets in our pipeline and will continue to lever our expertise in drug development and commercialization to further grow our business."

GUIDANCE:

Aquestive Therapeutics Inc. sees FY2019 revenue of $33-45 million, versus the consensus of $48.62 million.

For earnings history and earnings-related data on Aquestive Therapeutics Inc. (AQST) click here.